Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
United Therapeutics Corporation's quarterly P/E stands at 25.5x, up 119.1% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has expanded 116.5% YoY to 20.6x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 20.43 | 25.47 | 15.90 | 14.64 | 11.21 | 11.62 | 14.25 | 14.02 | 13.61 | 9.31 | 12.61 | 10.50 | 10.53 |
| — | +119.1% | +11.6% | +4.4% | -17.7% | +24.9% | +13.0% | +33.6% | +29.3% | -19.2% | -51.6% | -1.5% | -56.9% | |
| P/S Ratio | 7.84 | 8.95 | 7.38 | 6.20 | 4.34 | 4.71 | 5.84 | 5.79 | 5.29 | 4.21 | 4.45 | 4.61 | 4.58 |
| — | +89.9% | +26.5% | +7.1% | -17.9% | +11.9% | +31.1% | +25.7% | +15.5% | -23.1% | -36.3% | -6.8% | -24.5% | |
| P/B Ratio | 3.84 | 4.74 | 3.29 | 3.01 | 1.93 | 2.20 | 2.67 | 2.84 | 2.66 | 2.14 | 1.83 | 1.97 | 2.02 |
| — | +115.5% | +23.3% | +5.8% | -27.2% | +2.9% | +45.7% | +44.7% | +31.5% | -1.4% | -36.1% | -12.1% | -23.1% | |
| P/FCF | 23.97 | 19.30 | 33.67 | 14.10 | 26.79 | 9.70 | 16.88 | 14.42 | 20.22 | 8.44 | 38.02 | 10.01 | 44.35 |
| — | +99.0% | +99.5% | -2.2% | +32.5% | +14.9% | -55.6% | +44.1% | -54.4% | +1.3% | -1.8% | -25.5% | +72.2% | |
| EV / EBITDA | 14.82 | 20.65 | 12.55 | 11.39 | 7.97 | 9.54 | 10.46 | 11.17 | 10.54 | 7.25 | 9.54 | 8.02 | 8.17 |
| — | +116.5% | +20.0% | +1.9% | -24.4% | +31.6% | +9.7% | +39.3% | +29.1% | -19.7% | -47.0% | +4.7% | -38.2% | |
| EV / EBIT | 15.67 | — | 12.18 | 10.60 | 7.39 | 7.96 | 9.76 | 10.15 | 11.16 | 6.53 | 8.41 | 8.35 | 8.50 |
| — | — | +24.8% | +4.4% | -33.8% | +21.7% | +16.1% | +21.6% | +31.2% | -25.6% | -54.2% | +7.1% | -53.0% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
United Therapeutics Corporation's operating margin was 41.7% in Q1 2026, down 3.5 pp QoQ and down 6.5 pp YoY. This marks the 3rd consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. The trailing four-quarter average of 45.3% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 6.1% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 87.9% | 82.9% | 86.9% | 87.4% | 89.0% | 88.4% | 89.7% | 88.9% | 89.1% | 89.2% | 88.4% | 88.5% | 89.3% |
| — | -6.1% | -3.1% | -1.7% | -0.1% | -1.0% | +1.4% | +0.5% | -0.2% | -0.5% | -0.2% | -4.6% | -4.7% | |
| Operating Margin | 46.9% | 41.7% | 45.1% | 48.6% | 45.6% | 48.2% | 48.6% | 45.8% | 44.7% | 52.6% | 42.3% | 53.7% | 52.5% |
| — | -13.5% | -7.1% | +6.1% | +2.0% | -8.3% | +14.9% | -14.6% | -14.8% | -6.3% | +18.4% | -11.9% | +21.6% | |
| Net Margin | 41.9% | 35.2% | 46.1% | 42.4% | 38.8% | 40.6% | 40.9% | 41.3% | 38.9% | 45.2% | 35.3% | 43.9% | 43.5% |
| — | -13.3% | +12.6% | +2.6% | -0.4% | -10.3% | +15.9% | -6.0% | -10.5% | -4.8% | +31.4% | -5.3% | +74.9% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 19.7% | 4.2% | 5.3% | 4.9% | 4.4% | 4.9% | 4.8% | 5.2% | 5.0% | 5.4% | 3.7% | 4.8% | 4.9% |
| — | -13.0% | +10.8% | -6.1% | -12.2% | -10.2% | +29.4% | +8.9% | +2.4% | +11.5% | +31.5% | -10.7% | +80.2% | |
| ROA | 17.5% | 3.8% | 4.8% | 4.4% | 4.0% | 4.3% | 4.2% | 4.5% | 4.2% | 4.5% | 3.1% | 3.9% | 4.0% |
| — | -11.7% | +15.0% | -0.6% | -6.0% | -5.0% | +35.9% | +14.3% | +5.7% | +15.4% | +37.0% | -7.6% | +87.0% | |
| ROIC | 21.1% | 4.7% | 4.9% | 5.3% | 5.1% | 5.7% | 5.4% | 5.3% | 5.0% | 5.3% | 3.6% | 4.7% | 4.7% |
| — | -16.6% | -9.3% | +0.5% | +1.6% | +7.5% | +49.7% | +13.1% | +6.1% | +15.8% | +22.9% | -14.0% | +33.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 12.2% YoY to 4.79x, tightening the short-term liquidity position.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 0.03 | 0.05 | 0.07 | 0.09 | 0.11 | 0.12 | 0.14 | 0.15 |
| — | — | — | — | — | -73.9% | -60.2% | -53.2% | -40.6% | -28.0% | -29.9% | -20.1% | -20.2% | |
| Debt / EBITDA | — | — | — | — | — | 0.57 | 0.79 | 1.10 | 1.48 | 1.62 | 2.56 | 2.35 | 2.45 |
| — | — | — | — | — | -64.5% | -68.9% | -53.0% | -39.8% | -39.9% | -39.7% | -3.8% | -34.3% | |
| Current Ratio | 6.60 | 4.79 | 6.60 | 6.40 | 7.26 | 5.46 | 5.25 | 4.58 | 4.35 | 3.77 | 4.41 | 4.65 | 8.68 |
| — | -12.2% | +25.8% | +39.6% | +66.9% | +44.7% | +18.9% | -1.5% | -49.9% | -61.6% | -55.2% | -52.0% | +7.2% | |
| Quick Ratio | 6.28 | 4.50 | 6.28 | 6.07 | 6.94 | 5.23 | 5.03 | 4.41 | 4.18 | 3.64 | 4.28 | 4.51 | 8.40 |
| — | -14.1% | +24.7% | +37.6% | +65.8% | +43.9% | +17.8% | -2.1% | -50.2% | -61.8% | -55.2% | -52.0% | +7.3% | |
| Interest Coverage | 88.89 | 108.60 | 144.23 | 147.00 | 56.95 | 68.43 | 51.19 | 39.48 | 27.58 | 30.97 | 20.56 | 20.96 | 21.18 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying UTHR stock.
United Therapeutics Corporation's current P/E is 20.4x. The average P/E over the last 4 quarters is 16.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
United Therapeutics Corporation's current operating margin is 46.9%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking United Therapeutics Corporation's business trajectory between earnings reports.